Akebia Therapeutics AKBA
NASDAQ AKBA
$0.87 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Akebia Therapeutics (AKBA) Return on Sales [ROS] (2017 - 2026)

Updated

Akebia Therapeutics (AKBA) recorded Return on Sales [ROS] of -12.88% in Q2 2026, down 35.43 percentage points from 22.55% a year earlier and down 4.11 percentage points from the prior quarter.

Analysis

Akebia Therapeutics (AKBA) Return on Sales [ROS] (2017 - 2026) Analysis & Trends

On a TTM basis, Akebia Therapeutics' Return on Sales [ROS] came in at -6.90% as of Jun 30, 2026, down 7.29 percentage points year-over-year; for FY2025, it came in at 9.95%, up 41.46 percentage points from FY2024.

  • Annual Return on Sales [ROS] has a five-year change of +138.18 percentage points (FY2020 to FY2025).
  • Across earlier years, Return on Sales [ROS] came in at -31.51% in FY2024 (-7.74 pp), -23.77% in FY2023 (+3.85 pp), -27.62% in FY2022 (+97.35 pp) and -124.97% in FY2021 (+3.26 pp).
  • Quarterly Return on Sales [ROS] has ranged from -113.28% in Q4 2021 to 26.97% in Q2 2022 over the past five years.
  • On a year-over-year basis, Return on Sales [ROS] rose in four of the last eight quarters, with an average year-over-year change of +8.18 percentage points.
  • Peak year-over-year performance for Return on Sales [ROS] in the last five years was a gain of 176.91 percentage points in Q2 2022, against a drop of 42.92 percentage points in Q2 2023 at the low end.
  • Per Business Quant, the preceding three quarters came in at -8.77% (Q1 2026), -14.84% (Q4 2025) and 7.57% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 28.21%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 37.86%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -3.52%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 32.97%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 20.57%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 34.95%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -133.21%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 28.37%
10 Akebia Therapeutics 236.42 Mn -433.06 Mn 38.70 Mn -12.88%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -12.88%
Mar 31, 2026 -8.77%
Dec 31, 2025 -14.84%
Sep 30, 2025 7.57%
Jun 30, 2025 22.55%
Mar 31, 2025 23.57%
Dec 31, 2024 -30.77%
Sep 30, 2024 -33.41%
Jun 30, 2024 -19.99%
Mar 31, 2024 -45.81%
Dec 31, 2023 2.45%
Sep 30, 2023 -31.00%
Jun 30, 2023 -15.96%
Mar 31, 2023 -63.98%
Dec 31, 2022 -8.73%
Sep 30, 2022 -103.47%
Jun 30, 2022 26.97%
Mar 31, 2022 -96.57%
Dec 31, 2021 -113.28%
Sep 30, 2021 -112.57%
API Access

Akebia Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=AKBA&period=max&api_key=YOUR_API_KEY